Michael M. Yang's Insider Trades & SAST Disclosures
Michael M. Yang's most recent trade in Ionis Pharmaceuticals Inc was a trade of 1,931 Restricted Stock Unit done . Disclosure was reported to the exchange on Jan. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael M. Yang.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | Michael J. Yang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 1,931 | 7,939 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael J. Yang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 1,931 | 1,931 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Michael J. Yang | Director | Purchase of securities on an exchange or from another person at price $ 12.90 per share. | 14 Aug 2024 | 2,000 | 7,230 (0%) | 0% | 12.9 | 25,800 | Common Stock |
| Ionis Pharmaceuticals Inc | Michael J. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 4,079 | 9,870 | - | - | Restricted Stock Unit | |
| Pacira BioSciences Inc | Michael J. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,179 | 12,179 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Michael J. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 5,230 | 5,230 (0%) | 0% | 0 | Common Stock | |
| Hanmi Financial Corp. | Michael M. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 4,040 | 27,476 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Yang J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 5,791 | 5,791 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael J. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 12,356 | 12,356 | - | - | Non-Qualified Stock Option (right to buy) | |
| Hanmi Financial Corp. | Michael M. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 4,334 | 23,436 (0%) | 0% | 0 | Common Stock | |
| Hanmi Financial Corp. | Michael M. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 2,194 | 19,102 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 2,722 | 8,167 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 2,722 | 9,179 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Sale of securities on an exchange or to another person at price $ 53.34 per share. | 06 Jan 2021 | 1,120 | 8,059 (0%) | 0% | 53.3 | 59,741 | Common Stock |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,500 | 5,000 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,500 | 7,704 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Sale of securities on an exchange or to another person at price $ 42.56 per share. | 15 Oct 2020 | 1,247 | 6,457 (0%) | 0% | 42.6 | 53,072 | Common Stock |
| Hanmi Financial Corp. | Michael M. Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 5,053 | 14,915 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Sale of securities on an exchange or to another person at price $ 56.05 per share. | 07 Jul 2020 | 16,150 | 16,304 (0%) | 0% | 56.1 | 905,212 | Common Stock |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 14,750 | 44,292 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.12 per share. | 07 Jul 2020 | 14,750 | 32,454 (0%) | 0% | 25.1 | 370,520 | Common Stock |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Sale of securities on an exchange or to another person at price $ 56.54 per share. | 07 Jul 2020 | 11,100 | 5,204 (0%) | 0% | 56.5 | 627,574 | Common Stock |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 7,500 | 570,000 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.98 per share. | 07 Jul 2020 | 7,500 | 12,704 (0%) | 0% | 20.0 | 149,850 | Common Stock |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Michael J. Yang | EVP and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.28 per share. | 07 Jul 2020 | 5,000 | 17,704 (0%) | 0% | 21.3 | 106,400 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges